Company intelligence / Profile preview

Curetis

Holzgerlingen, Baden-Württemberg, Germanycuretis.com ↗

Ownership: Private
Development stage: Commercial

Overview

Curetis’ Unyvero system provides rapid (<5 hours) sample-to-answer molecular diagnostic testing for severe infectious diseases. Clinical trials demonstrated high sensitivity (~91%) and specificity (~99.5–99.8%) compared to standard microbiology culture methods that take several days. The system has CE-marking in Europe and FDA clearance in the US for certain applications.

Therapeutic areas: Infectious Diseases
Modalities: DeviceMolecular diagnostics platform
Industry: Molecular Diagnostics

Partnerships

Heraeus Medical (joint development of ITI cartridge)Cempra Inc.A.Menarini Diagnostics (exclusive pan-European distribution partnership)

Beyond the preview

Go deeper on Curetis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Curetis.

Explore the full profile